Clinical Trial Update: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Suratadenoturev (OBP-301) in combination with pembrolizumab for esophagogastric adenocarcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Suratadenoturev (OBP-301)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Status: RECRUITING